Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Gerd R Burmester; Joel M Kremer; Filip Van den Bosch; Alan Kivitz; Louis Bessette; Yihan Li; Yijie Zhou; Ahmed A Othman; Aileen L Pangan; Heidi S Camp

doi:10.1016/s0140-6736(18)31115-2

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)31115-2 ◽

2018 ◽

Vol 391 (10139) ◽

pp. 2503-2512 ◽

Cited By ~ 114

Author(s):

Gerd R Burmester ◽

Joel M Kremer ◽

Filip Van den Bosch ◽

Alan Kivitz ◽

Louis Bessette ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Disease Modifying

Download Full-text

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

Arthritis & Rheumatism ◽

10.1002/art.27524 ◽

2010 ◽

Vol 62 (8) ◽

pp. 2227-2238 ◽

Cited By ~ 69

Author(s):

Mikkel Østergaard ◽

Bo Baslund ◽

William Rigby ◽

Bernadette Rojkovich ◽

Christian Jorgensen ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase I ◽

Inadequate Response ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Anti Cd20

Download Full-text

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)31116-4 ◽

2018 ◽

Vol 391 (10139) ◽

pp. 2513-2524 ◽

Cited By ~ 119

Author(s):

Mark C Genovese ◽

Roy Fleischmann ◽

Bernard Combe ◽

Stephen Hall ◽

Andrea Rubbert-Roth ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Disease Modifying ◽

Randomised Controlled

Download Full-text

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Download Full-text

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

RMD Open ◽

10.1136/rmdopen-2014-000037 ◽

2015 ◽

Vol 1 (1) ◽

pp. e000037 ◽

Cited By ~ 12

Author(s):

Michael Schiff ◽

Bernard Combe ◽

Thomas Dörner ◽

Joel M Kremer ◽

Thomas W Huizinga ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tnf Inhibitors ◽

Inadequate Response ◽

Efficacy And Safety ◽

Severe Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of an Anti-RANKL Antibody Denosumab on Joint Structural Damage in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DESIRABLE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3234849 ◽

2018 ◽

Author(s):

Tsutomu Takeuchi ◽

Yoshiya Tanaka ◽

Satoshi Soen ◽

Hisashi Yamanaka ◽

Toshiyuki Yoneda ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Structural Damage ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying

Download Full-text

086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

Rheumatology ◽

10.1093/rheumatology/kez106.085 ◽

2019 ◽

Vol 58 (Supplement_3) ◽

Author(s):

David Walker ◽

Mark C Genovese ◽

Kenneth Kalunian ◽

Jacques-Eric Gottenberg ◽

Kurt de Vlam ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Safety And Efficacy ◽

Disease Modifying

Download Full-text

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

Arthritis & Rheumatism ◽

10.1002/art.33317 ◽

2012 ◽

Vol 64 (2) ◽

pp. 350-359 ◽

Cited By ~ 42

Author(s):

W. Rigby ◽

H.-P. Tony ◽

K. Oelke ◽

B. Combe ◽

A. Laster ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase Iii ◽

Inadequate Response ◽

Double Blind ◽

Phase Iii Trial ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial

Modern Rheumatology ◽

10.3109/14397595.2013.843756 ◽

2013 ◽

Vol 24 (3) ◽

pp. 410-418 ◽

Cited By ~ 33

Author(s):

Masako Hara ◽

Naoki Ishiguro ◽

Kou Katayama ◽

Masakazu Kondo ◽

Takayuki Sumida ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Combination Therapy ◽

Active Rheumatoid Arthritis ◽

Controlled Trial ◽

Inadequate Response ◽

Open Label ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Open Label Extension

Download Full-text

Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164186.624873 ◽

2009 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text